Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Dexamethasone 4filanesib 2daratumumab 2Steroids 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Bortezomib 2silmitasertib 1pomalidomide 1milatuzumab 1Proteasome Inhibitors 1Leukapheresis 1CF regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Plasmacytoma × milatuzumab × Clear all
NCT00421525 2021-08-16

Phase I/II Study of hLL1 in Multiple Myeloma

Gilead Sciences

Phase 1/2 Completed
25 enrolled
Plasma cell

Multiple Myeloma, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡